Beta Drugs Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Beta Drugs Ltd is ₹ 1330 as of 30 Apr 15:30 . The P/E Ratio of Beta Drugs Ltd changed from 32.5 on March 2024 to 19.6 on March 2023 . This represents a CAGR of -9.62% over 5 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years The Market Cap of Beta Drugs Ltd changed from ₹ 1186 crore on March 2024 to ₹ 602.74 crore on March 2023 . This represents a CAGR of -12.66% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 years The revenue of Beta Drugs Ltd for the Dec '25 is ₹ 89.58 crore as compare to the Sep '25 revenue of ₹ 106.37 crore. This represent the decline of -15.78% The revenue of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 22.36 crore as compare to the Sep '25 revenue of ₹ 15.66 crore. This represent the growth of 42.78% The ebitda of Beta Drugs Ltd for the Dec '25 is ₹ 19.3 crore as compare to the Sep '25 ebitda of ₹ 24.3 crore. This represent the decline of -20.58% The ebitda of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 4.13 crore as compare to the Sep '25 ebitda of ₹ 2.41 crore. This represent the growth of 71.37% The net profit of Beta Drugs Ltd changed from ₹ 8.95 crore to ₹ 8.52 crore over 5 quarters. This represents a CAGR of -3.86% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 2.78 crore over 7 quarters. This represents a CAGR of 32.01% The Dividend Payout of Beta Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Beta Drugs Ltd

Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005.
Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group.
Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India.
The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers.
The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Beta Drugs Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Beta Drugs Ltd or Sanjivani Paranteral Ltd?

Market cap of Beta Drugs Ltd is 1,348 Cr while Market cap of Sanjivani Paranteral Ltd is 196 Cr

What are the key factors driving the stock performance of Beta Drugs Ltd and Sanjivani Paranteral Ltd?

The stock performance of Beta Drugs Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Beta Drugs Ltd and Sanjivani Paranteral Ltd?

As of May 4, 2026, the Beta Drugs Ltd stock price is INR ₹1330.1. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹160.0.

How do dividend payouts of Beta Drugs Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Beta Drugs Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.